Abstract
Even though the current market environment is tough on biotechnology companies, the number of consolidation transactions in Europe has fallen. Platform specialists have to turn themselves into product companies in order to be heard by investors. Product companies are crushed between high financing needs and their cost of capital. A full integration strategy can destroy value for founders and early investors. Thorough analysis, good strategic fit, a rigorous integration plan and retaining the talent are predictors of success in a merger situation. Engineering the future value proposition around fundamental drivers of investor return determines mid-term access to capital. Trade sales are becoming a very lucrative exit route, provided the assets meet expectations of the pharmaceutical industry.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stoiber, W. Consolidation challenges in Europe's life science sector – Making it happen. J Commer Biotechnol 10, 29–34 (2003). https://doi.org/10.1057/palgrave.jcb.3040052
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1057/palgrave.jcb.3040052